©
icddr,b
The TyVOID study, published in the Lancet, measured the effectiveness of a single dose TCV in Bangladeshi children over a five-year period and confirmed the high vaccine protection (80-96%) within two years of vaccination in all children.
Three to five years after vaccination, the study found a three-fold increase in typhoid incidence in children who received TCV in 2018/2019 and those who received it in 2021, suggesting a decline in vaccine effectiveness, most pronounced in the very young. The data suggested children vaccinated at two years or older were still well protected (59-85%) at 3-5 years post vaccination however, a more significant decline in protection was seen in children vaccinated at under two years of age, suggesting that a booster dose for these children might be needed for sustained protection.
Xinxue Liu, Associate Professor of Medical Statistics and Epidemiology at the Oxford Vaccine Group, and one of the senior authors of the study, said: 'Typhoid is a serious and life-threatening enteric fever that remains a substantial public health issue for children and adolescents in low- and middle-income countries. TCV offers the best chance to reduce the burden of typhoid, helping to reduce transmission and limiting further evolution of drug-resistant strains. This study provides additional information for policy makers on longer-term TCV protection and the importance of continued investigation and updated guidance.'